Court et al. found that vimentin-positive CTCs can not only help diagnose and stage HCC but also accurately discriminate patients eligible for liver transplant (median, 0 vimentin-positive CTCs) from patients with locally advanced/metastatic disease ineligible for liver transplant (median, 6 vimentin-positive CTCs). The gene discussed is VIM; the disease is hepatocellular carcinoma.